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Background: Full-field digital mammography (FFDM) has replaced screen-film mammography (SFM) in most breast cancer
screening programs due to technological advantages such as possibilities to adjust contrast, better image quality and transfer
capabilities. This study describes the performance indicators during the transition from SFM to FFDM and the characteristics of
screen-detected and interval cancers.
Methods: Data of the Dutch breast cancer screening program, region North from 2004 to 2010 were linked to The Netherlands
Cancer Registry (N¼ 902 868). Performance indicators and tumour characteristics of screen-detected and interval cancers were
compared between FFDM and SFM.
Results: After initial screens, recall rates were 2.1% (SFM) and 3.0% (FFDM; Po0.001). The positive predictive values (PPV) were
25.6% (SFM) and 19.9% (FFDM; P¼ 0.002). Detection rates were similar, as were all performance indicators after subsequent
screens. Similar percentages of low-grade ductal carcinoma in situ (DCIS) were found for SFM and FFDM. Invasive cancers
diagnosed after subsequent screens with FFDM were more often of high-grade (P¼ 0.024) and ductal type (P¼ 0.030). The
incidence rates of interval cancers were similar for SFM and FFDM after initial (2.69/1000 vs 2.51/1000; P¼ 0.787) and subsequent
screens (2.30 vs 2.41; P¼ 0.652), with similar tumour characteristics.
Conclusions: FFDM resulted in similar rates of screen-detected and interval cancers, indicating that FFDM performs as well as
SFM in a breast cancer screening program. No signs of an increase in low-grade DCIS (which might connote possible
overdiagnosis) were seen. Nonetheless, after initial screening, which accounts for 12% of all screens, FFDM resulted in higher
recall rate and lower PPV that requires attention.
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In recent years, screen-film mammography (SFM) has been
replaced by full-field digital mammography (FFDM) in most
Western breast cancer screening programs. The main reasons are a
better image quality and dose optimisation, and easier and more
efficient archiving and image transfer capabilities (Obenauer et al,
2002; Pisano and Yaffe, 2005).
Studies have shown that FFDM does not result in differences in
cancer detection rate (Vinnicombe et al, 2009; Juel et al, 2010;
Domingo et al, 2011) or higher overall breast cancer detection
compared with SFM in the clinical as well as in a population-based
setting (Lewin et al, 2001; Pisano et al, 2005; Del Turco et al, 2007;
Glynn et al, 2011). However, others have shown a higher detection
rate only for ductal carcinoma in situ (DCIS) (Vigeland et al, 2008;
Karssemeijer et al, 2009). Furthermore, FFDM results in a higher
recall rate, in combination with higher detection rates and
decreased positive predictive values (PPV) of recall (Skaane et al,
2007; Bluekens et al, 2012). Nevertheless, the opposite effect on
recall rate and PPV has also been described (Hofvind et al, 2014).
The recall and detection rates for SFM vary between different
screening programs. These differences in ‘baseline’ measurements
might partly explain the different outcomes for the introduction of
FFDM when comparing with SFM.
FFDM seems associated with an increase in smaller cancers and
DCIS (Del Turco et al, 2007; Vigeland et al, 2008; Bluekens et al,
2012; van Luijt et al, 2013). It remains uncertain to which extent
this might be associated with overdiagnosis and a wide range of
overdiagnosis estimates exist (Jørgensen and Gøtzsche, 2009).
Furthermore, some studies comparing FFDM with SFM have
analysed tumour characteristics other than DCIS and report no
differences in tumour characteristics such as T- or N-stage
(Vigeland et al, 2008; Juel et al, 2010; Domingo et al, 2011;
Bluekens et al, 2012). However, one study found that FFDM
detected more lymph node-negative and hormone receptor-
positive cancers (Nederend et al, 2012). Studies about the incidence
of interval cancers so far report no differences in interval cancer
rates between SFM and FFDM (Juel et al, 2010; Hofvind et al,
2014). As the recall rate in The Netherlands is lower than in other
countries with population-based screening programs, the transition
from SFM to FFDM might lead to different conclusions regarding
interval cancer rates. However, data regarding interval cancers in
the Dutch situation, with a national screening program, is still
scarce (Nederend et al, 2013).
The objective of this study was to evaluate whether the
transition from SFM to FFDM resulted in changes in the recall
rate, PPV, the detection rate of DCIS and invasive cancers and
tumour characteristics of screen-detected cancers in the Dutch
screening program. Moreover, the rate and tumour characteristics
of interval cancers were compared, as were program sensitivity and
specificity.
MATERIALS AND METHODS
Setting. In The Netherlands, a national population-based screen-
ing program is operational since 1990, inviting women 50–69 years
of age for a biennial screening examination (Fracheboud et al,
2001). Women 70–75 years of age are included from 1999
onwards. All mammographic examinations are performed by
specialised radiographers. Recall for further diagnostic work-up
was indicated in case of incomplete examination (BI-RADS 0) or
suspicious or malignant findings (BI-RADS 4 or 5)(D’Orsi et al,
2003; Timmers et al, 2012). The screening program started in 1990
using screen-film mammography. In 2003 the first digital
mammography unit was introduced and in 2010 all screening
examinations were performed using digital mammography. By
participating in the screening program, women consent to the use
of their data to evaluate the program. Information about the use of
their data is provided in a flyer accompanying the letter of
invitation. If a woman does not want her data being used for this
purpose, she can return a signed form to the screening
organisation. Only a minor fraction of screened women (0.01%)
uses this option (Fracheboud et al, 2014).
Data on cancer is registered in The Netherlands Cancer Registry
(NCR). The NCR is a population-based database, which contains
data on patient, tumour and treatment characteristics of all in situ
and invasive malignancies diagnosed in The Netherlands. This
study was approved by the Committee of Privacy of The
Netherlands Comprehensive Cancer Organisation (IKNL), which
hosts the NCR.
Women and data. All women (50–75 years) who underwent a
screening examination between 2004 and 2010 in the Dutch Breast
Cancer Screening Program, region North-Netherlands were
included. The target population of this area comprised B300 000
women, of whom about 150 000 were invited each year. The region
North-Netherlands followed the national program. It started in
1991 with SFM and implemented the first digital mammography in
2003. During 2009, the remaining seven screen-film mammogra-
phy units were replaced by digital mammography units. The
screening data included all dates and results of the screening
examinations. These screening data were linked to data of the
NCR. The main source of notification for the NCR is PALGA, the
nationwide Dutch network and registry of histo and cytological
pathology. After notification to the NCR, specially trained
registration clerks visit the hospitals to collect information on
patient and tumour characteristics, stage and treatment from
patient files. Coding of the items is based on international coding
rules. For the staging of cancers, TNM classification is used
(Wittekind et al, 2004).
Image acquisition and interpretation. SFM images were acquired
with two types of systems (GE 600/800T, GE Healthcare, Buc,
France). Digital mammograms were acquired by using Embrace
DR (Agfa-Gevaert, Mortsel, Belgium) or Lorad Selenia FFDM
systems (Hologic, Danbury, CT, USA). Initial screening examina-
tions performed with SFM or FFDM always included two standard
views, craniocaudal and mediolateral oblique. At subsequent
screening examinations, mediolateral oblique views were routinely
acquired, craniocaudal views were acquired if indicated by criteria
based on, among others, breast density and visible abnormality.
Radiologists interpreted mammograms made by SFM as well as
FFDM. Mammograms were interpreted in batch mode and were
independently read by two radiologists. Differences in opinion
were resolved by consensus. In subsequent screens with SFM as
well as FFDM, prior mammograms were available for comparison.
To facilitate soft-copy reading of subsequent screening examina-
tions with FFDM, the most recent screen-film mediolateral oblique
and craniocaudal views were digitised by using film scanners and
archiver designed for mammography (IMPAX TS5 transmit
scanner, Agfa-Gevaert; DigitalNow, Hologic).
Definitions. Women with a ‘screen-detected cancer’ were defined
as women having a positive screening examination at the breast
cancer screening program, which was subsequently followed by a
diagnosis of breast cancer within 12 months. The second group
comprised women with an ‘interval cancer’, that is, women who,
despite a negative examination at the breast cancer screening, were
diagnosed with breast cancer within 24 months. In the analysis,
women with screen-detected breast cancer and women with
interval cancer were considered separately. Recall rate was defined
as the proportion of women with a positive screening examination
out of all screened women. Detection rate was defined as the
proportion of women diagnosed with breast cancer out of all
screened women and PPV was calculated as the percentage of
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women with screen-detected breast cancer out of all recalled
women. All screening examinations from 2004 to 2010 were
considered for the calculation of recall rate, detection rate and PPV
(n¼ 902 868). Program sensitivity was defined as the proportion of
screen-detected breast cancers out of all breast cancers (interval
cancers plus screen-detected cancers). Program specificity was
defined as the proportion of women without breast cancer with a
negative examination (true negatives) out of all women without
breast cancer (true negatives plus false positives). Program
sensitivity, program specificity and the incidence of interval
cancers were calculated for women screened from 2004 to 2008.
As follow up was complete until 2010, the complete number of
breast cancer cases, including interval cancers can be diagnosed up
to 24 months after the last screening examination (n¼ 638 663).
For women with bilateral disease, the tumour with the highest
stage was selected. Tumour stage was defined according to the
greatest dimension of the largest tumour size (T1a: p0.5 cm, T1b:
40.5 cm and p1 cm, T1c: 41 cm and p2 cm, T2þ : 42 cm).
Statistical analysis. SFM and FFDM were compared regarding the
performance indicators (recall rate, detection rate and PPV), tumour
characteristics of screen-detected cancers, incidence rate and tumour
characteristics of interval cancers, program sensitivity and program
specificity. The comparison was stratified by initial and subsequent
screening examinations. Pearson w2-tests or Fisher exact tests were
applied. Missing values in tumour characteristics were excluded in
the statistical comparison. Variation in recall and detection rate per
year was graphically visualised for SFM and FFDM, stratified by
initial and subsequent screening examinations. The statistical
significance level was set at a P-value o0.05. Analyses were
performed using the STATA software package, version 13.1 for
Windows (Stata Corporation LP, College Station, TX, USA).
RESULTS
In the period 2004–2010 in total 902 868 screening examinations
were performed by the Dutch Breast Cancer Screening Program,
region North-Netherlands, of which 255 633 (28%) by FFDM.
Twelve percent of the 647.235 examinations by SFM were initial
examinations; for FFDM, this was 11% (Table 1).
Recall rate, detection rate and positive predictive value. The
recall rate after initial examination of 2.1% for SFM remained
stable during the study period (Table 1). For FFDM the recall rate
of 3.0% proved to be significantly higher than for SFM (Po0.001).
After the complete introduction of FFDM, the recall rate decreased
to 2.8% in 2010 and was still significantly higher than the recall
rate of 2.1% for SFM (Po0.001) (Figure 1A).
After initial examination, the detection rate for DCIS was 0.86 per
1000 women for SFM compared with 1.18 per 1000 women for FFDM
(P¼ 0.137). For invasive cancers, detection rates were 4.42 per 1000
women for SFM and 4.83 per 1000 women for FFDM (P¼ 0.338).
During the total period, the overall detection rate for SFM remained
fairly constant. For FFDM the detection rate fluctuated markedly, due
to small numbers (Figure 1B). The PPV after initial examination was
25.6% for SFM and 19.9% for FFDM (P¼ 0.002).
After subsequent examinations, the overall recall rate for SFM
was 1.2% and for FFDM, after an initially high rate, 1.1%
(P¼ 0.532; Table 1; Figure 1C.) The overall detection rates were
5.28 per 1000 women for SFM and 5.14 per 1000 women for
FFDM (P¼ 0.638; Table 1). No differences were found in detection
rates for DCIS (0.74 per 1000 women for SFM vs 0.81 per 1000
women for FFDM; P¼ 0.298), nor for invasive cancers (4.54 per
1000 women for SFM vs 4.33 per 1000 women for FFDM;
P¼ 0.210). The detection rate remained stable over the years for
SFM as well as FFDM (Figure 1D). Positive predictive values were
45.7 and 45.2% for SFM and FFDM, respectively (P¼ 0.638).
Tumour characteristics of screen-detected cancers. After initial
examinations, no differences were found in tumour characteristics
(Table 2), but a non-significant trend towards more T1a cancers
was seen (4.7% for SFM and 10.6% after FFDM, P¼ 0.138). In
16.3% of all cancers a DCIS was diagnosed after SFM, compared
with 19.6% after FFDM (P¼ 0.335). After subsequent examina-
tions, DCIS was diagnosed in 14.0% of all cancers after SFM, 15.8%
after FFDM (P¼ 0.139). After FFDM a significantly larger part of
invasive cancers were ductal cancers (SFM: 81.6%, FFDM: 85.1%;
P¼ 0.030) and the cancers were more often high-grade (SFM:
9.0%, FFDM: 23.4%; P¼ 0.024).
Incidence rate of interval cancers, program sensitivity and
specificity. Overall incidence rates of interval cancers were similar
with 2.35 per 1000 women for SFM and 2.42 per 1000 women for
FFDM (P¼ 0.748). After initial screens, no difference was found in
the incidence of interval cancers with 2.69 per 1000 women for SFM
and 2.51 per 1000 women for FFDM (P¼ 0.787, Table 3). The
sensitivity after initial examinations was 66.1% for SFM and 69.1%
for FFDM (P¼ 0.657), specificity was 98.5% and 96.9% for SFM and
FFDM, respectively (Po0.001). After subsequent examinations, the
overall incidence rate of all interval cancers was 2.30 per 1000 women
for SFM and 2.41 per 1000 women for FFDM (P¼ 0.652), the
sensitivity was 69.7% for SFM and 66.7% for FFDM (P¼ 0.232).
Specificity was 99.4% SFM and 99.2% for FFDM (Po0.001).
Tumour characteristics of interval cancers. No differences were
found in the tumour characteristics of interval cancers diagnosed
after FFDM compared with SFM after initial or after subsequent
examinations (Table 4).
DISCUSSION
After initial screens with FFDM, we found a higher recall rate and a
lower PPV. No difference was found in the proportion and
malignancy grade of DCIS. Tumour characteristics of invasive
cancers and the incidence rate and tumour characteristics of
interval cancers were similar. After subsequent screens the
proportion of DCIS was similar for SFM and FFDM. After FFDM,
a significantly larger part of invasive cancers were ductal cancers
and high-grade. No differences were found in the incidence of
interval cancers or their tumour characteristics between SFM and
FFDM.
In our study a higher recall rate and lower PPV were found after
initial screens with FFDM, which accounts for 12% of all screens,
but no differences were found after subsequent screens. A
systematic review by Vinnicombe et al (2009) showed that recall
rates varied greatly with some studies showing lower and others
showing higher recall rates for FFDM. We did not find a higher
detection rate, which is in line with some other studies (Del Turco
et al, 2007; Vinnicombe et al, 2009; Juel et al, 2010; Domingo et al,
2011). In contrast, other studies reported higher detection rates for
FFDM (Glynn et al, 2011; van Luijt et al, 2013), including a Dutch
study. The latter study also describes some variation in detection
rates between regions within The Netherlands. As our study only
included data from one region and the study could not interfere
with the ongoing screening program, existing variation between
regions and countries before the introduction of FFDM might
explain the different results and might have an effect on the
generalisability of our results. In the first years using FFDM, recall
and detection rates fluctuated. This might be due to a learning
curve, which has been described before (Bluekens et al, 2010), in
combination with the relative low number of FFDM screens
performed in comparison with SFM. As SFM was already in use since
the start of the program, recall and detection rates remained stable
during this study period as expected. The overall increase in recall rate
after FFDM is probably due to a higher resolution and the possibilities
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Table 1. Performance indicators of women (50–75 years) screened, recalled and positive predictive value for SFM and FFDM
(2004–2010)
SFM FFDM
2004–2010 N % N % P-value
Screened women 647 235 255 633
Initial screens 76 642 11.8 27 947 10.9
Subsequent screens 570 593 88.2 227 686 89.1
Recalled women 8174 1.26 3436 1.34 0.002
Initial screens 1584 2.07 844 3.02 o0.001
Subsequent screens 6590 1.15 2592 1.14 0.532
Screen-detected N Ratea PPV N Ratea PPV P-valueb P-valuec
Breast cancers 3418 5.28 41.8 1339 5.24 39.0 0.800 0.004
Initial screens 405 5.28 25.6 168 6.01 19.9 0.159 0.002
Subsequent screens 3013 5.28 45.7 1171 5.14 45.2 0.445 0.638
DCIS 489 0.76 6.0 218 0.85 6.3 0.137 0.456
Initial screens 66 0.86 4.2 33 1.18 3.9 0.137 0.761
Subsequent screens 423 0.74 6.4 185 0.81 7.1 0.298 0.213
Invasive cancers 2929 4.53 35.8 1121 4.39 32.6 0.369 0.001
Initial screens 339 4.42 21.4 135 4.83 16.0 0.385 0.001
Subsequent screens 2590 4.54 39.3 986 4.33 38.0 0.208 0.264
Abbreviations: DCIS¼ductal carcinoma in situ; FFDM¼ full-field digital mammography; PPV¼positive predictive values; SFM¼ screen-film mammography.
aDetection rates per 1000 women screened.
bEstimated p-values are based on comparison between rate.
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Figure 1. Recall and detection rates. (A) Percentage of women recalled after initial screens. (B) Detection rate per 1000 screened women after
initial screens. (C) The percentage of women recalled after subsequent screens. (D) Detection rate per 1000 screened women after subsequent
screens. Of the women with SFM as initial examination, 92% were aged 50–54 years, compared with 95% of women with FFDM as initial
examination. For subsequent examinations, 18 and 17% were aged 50–54 years for SFM and FFDM, respectively; 16% were aged 70–75 years for
SFM as well as FFDM.
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to adjust contrast. After FFDM, women are more often recalled due to
microcalcifications, which might be the result of this contrast
adjustment (Bluekens et al, 2010; Nederend et al, 2012).
Unfortunately, we did not have any information if the higher recall
rate after initial screens with FFDM lead to an increased number of
biopsies performed in patients with a false-positive result.
Table 2. Tumour characteristics of screen-detected cancers in women 50–75 years of age for SFM and FFDM (2004–2010)
Initial screen Subsequent screen
SFM FFDM SFM FFDM
N % N % P-value N % N % P-value
DCIS
Grade
Low 11 17.5 4 13.8 0.860 47 11.7 15 8.6 0.524
Intermediate 25 39.7 13 44.8 132 32.9 61 34.9
High 27 42.9 12 41.4 222 55.4 99 56.6
Unknown 3 4 22 10
DCIS, total 66 33 423 185
Invasive cancers
Tumour size
T1a 16 4.7 14 10.6 0.138 137 5.3 72 7.4 0.126
T1b 57 16.9 22 16.7 645 25.2 237 24.3
T1c 171 50.7 63 47.7 1296 50.6 476 48.9
T2þ 93 27.6 33 25.0 483 18.9 189 19.4
Unknown 2 3 29 12
Morphology 0.030
Ductal 293 86.4 115 85.2 0.089 2114 81.6 839 85.1
Lobular 37 10.9 11 8.1 345 13.3 113 11.5
Other 9 2.7 9 6.7 131 5.1 34 3.4
Grade
Low 105 32.3 46 37.7 0.469 813 32.5 268 28.5 0.024
Intermediate 151 46.5 55 45.1 1188 47.5 451 48.0
High 69 21.2 21 17.2 498 19.9 220 23.4
Unknown 14 13 91 47
Lymph node status
Negative 208 62.7 84 62.7 0.994 1859 73.1 717 73.5 0.794
Positive 124 37.3 50 37.3 684 26.9 258 26.5
Unknown 7 1 47 11
Invasive cancers, total 339 135 2590 986
Abbreviations: DCIS¼ductal carcinoma in situ; FFDM¼ full-field digital mammography; SFM¼ screen-film mammography.
Table 3. Women (50–75 years) screened, recalled and the number of women with screen-detected or interval cancers
(2004–2008)
SFM FFDM
2004–2008 N % N % P-value
Screened women 582869 55794
Initial screens 69 529 11.9 6768 12.1
Subsequent screens 51 334 88.1 49 026 87.9
Screen-detected N Ratea N Ratea
Breast cancers 3089 5.30 274 4.91 0.226
Initial screens 365 5.25 38 5.61 0.692
Subsequent screens 2724 5.31 236 4.81 0.150
Interval
Breast cancers 1370 2.35 135 2.42 0.748
Initial screens 187 2.69 17 2.51 0.787
Subsequent screens 1183 2.30 118 2.41 0.652
DCIS 67 0.11 4 0.07 0.525
Initial screens 8 0.12 1 0.15 0.567
Subsequent screens 59 0.11 3 0.06 0.370
Invasive cancers 1303 2.24 131 2.35 0.592
Initial screens 179 2.57 16 2.36 0.743
Subsequent screens 1124 2.19 115 2.35 0.481
Abbreviations: DCIS¼ductal carcinoma in situ; FFDM¼ full-field digital mammography; SFM¼ screen-film mammography.
aRates per 1000 women screened.
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After initial screens, no differences in tumour characteristics
between SFM and FFDM were found, which might indicate that
FFDM performs similar for the entire spectrum of breast cancer.
However, a non-significant trend towards more T1a cancers was
seen after initial screens with FFDM. To further analyse this, the
percentages of T1a cancers of all invasive cancers diagnosed after
initial FFDM (10.6%) and SFM (4.7%) in this regional study were
compared with the percentage of T1a cancers in initially screened
women in the total Dutch population. For the period 1990–2007
(when most women were screened with SFM) this percentage was
around 4% (Fracheboud et al, 2009). As we found a similar rate for
SFM, this indicates that our data can be representative of the Dutch
data and the trend towards more T1a cancers might be of interest.
In literature a non-significant increase in T1a-c cancers was
described, but the T1a cancers were not studied separately
(Nederend et al, 2012).
After subsequent screens with FFDM, more ductal and
high-grade invasive cancers were found, whereas other char-
acteristics were similar. Another Dutch, multicentre study found
no differences in grade in invasive cancers after subsequent
screens (Bluekens et al, 2012). Our findings also differ from
two Norwegian studies reporting no differences in tumour
characteristics in the total screened population (Hofvind et al,
2014). These differences are interesting as they may reflect
possible underlying differences in screening education or
performance.
Overdiagnosis will always remain an issue in screening
programs. It is accepted as an inevitable side effect of
the screening program, but the debate to which extent
overdiagnosis is acceptable still continues (Independent
Uk Panel on Breast Cancer Screening, 2012a,b). Overdiagnosis
can be defined as a malignancy that, if left undetected and
untreated, never would have surfaced in a person’s lifetime.
An increase in low-grade DCIS might connote possible
overdiagnosis. However, in our study we did not find a higher
incidence of DCIS nor did we find more low-grade DCIS after
FFDM compared with SFM. Another study did report a higher
incidence of DCIS, but no differences in the distribution
of grade (Bluekens et al, 2012). In contrast to our study, others
did report that FFDM resulted in differences in grade. However,
these studies reported opposite effects either towards more
high-grade DCIS (Vigeland et al, 2008) or towards more
low-grade DCIS (Nederend et al, 2012). Furthermore, any effect
on breast cancer mortality is still unknown.
We found no decrease in the incidence rate of interval cancers
after FFDM. The incidence of interval cancers for SFM and FFDM
was similar, which is in concordance with a randomised trial
comparing SFM and FFDM (Skaane et al, 2007). The rates of
interval cancers in the Norwegian population-based screening
program were also similar to our study (Hofvind et al, 2014).
In addition, tumour characteristics did not differ between
interval cancers diagnosed after SFM and FFDM, which is
in concordance with other studies (Nederend et al, 2013;
Hofvind et al, 2014).
The program sensitivity of SFM and FFDM found in the
present study were both lower than in the study by Nederend
Table 4. Tumour characteristics of interval cancers in women 50–75 years of age for SFM and FFDM (2004–2008)
Initial screen Subsequent screen
SFM FFDM SFM FFDM
N % N % P-value N % N % P-value
DCIS
Grade
Low 1 12.5 0 0 11 22.4 1 33.3
Intermediate 2 25 1 100 11 22.4 0 0
High 5 62.5 0 0 27 55.1 2 66.7
Unknown 10 0
DCIS, total 8 1 59 3
Invasive cancers
Tumour size
T1a 3 1.7 0 0 0.288 27 2.5 2 1.8 0.457
T1b 13 7.3 2 12.5 80 7.4 13 11.7
T1c 67 37.9 9 56.3 419 38.7 41 36.9
T2þ 94 53.1 5 31.3 557 51.4 55 49.5
Unknown 2 0 41 4
Morphology
Ductal 143 79.9 11 68.8 0.325 850 75.6 85 73.9 0.868
Lobular 31 17.3 5 31.3 196 17.4 22 19.1
Other 5 2.8 0 0 78 6.9 8 7
Grade
Low 34 20.2 1 7.1 0.384 178 18.1 14 13.6 0.523
Intermediate 67 39.9 5 35.7 417 42.4 46 44.7
High 67 39.9 8 57.1 389 39.5 43 41.7
Unknown 11 2 140 12
Lymph node
status
Negative 94 52.8 9 56.3 0.792 575 52.6 66 58.4 0.240
Positive 84 46.9 7 43.8 518 47.4 47 41.6
Unknown 1 0 31 2
Invasive, cancers
total
179 16 1124 115
Abbreviations: DCIS¼ductal carcinoma in situ; FFDM¼ full-field digital mammography; SFM¼ screen-film mammography.
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et al (2013), performed in another Dutch region. A Norwegian
study found a slightly higher sensitivity for FFDM and lower for
SFM than in our study (Skaane et al, 2007). Both studies did not
discriminate between initial and subsequent screens, which
might explain the differences. Compared with the program
sensitivity of the complete Dutch program of 70% after initial
screens and 71% after subsequent screens (Fracheboud et al,
2014), our study found a slightly lower sensitivity. The program
sensitivity has been stable at this level since at least 2004
and the Health Council of The Netherlands advised to continue
the organised screening program (Health Council of
The Netherlands, 2014).
Our study has several strengths and limitations. In the
current study, initial and subsequent screening examinations
were analysed separately, increasing the insight of the effects
of FFDM. Furthermore, this is a large population-based study
using standardised collected data from the NCR, including
tumour characteristics on tumour size, morphology, grade and
lymph node status. Data on oestrogen or progesterone receptor
or HER2neu status were not available for this cohort.
A limitation in comparing results with other studies might
lie in the fact that the Dutch screening program invites women
50–75 years of age, which differs from other screening programs
mostly offering screening to women 50–69 years old. This might
limit the generalisability of our results. Second, in The Nether-
lands, screening examinations are independently read by two
radiologists and – particularly in the Northern region – recall
rates are relatively low. Comparing FFDM with SFM might
therefore lead to different conclusions in comparison with other
studies. Furthermore, a Dutch study found variation in recall
rate, with less variation in detection rate, between regions in
The Netherlands (van Luijt et al, 2013). Finally, during this
study period a policy change towards making standard
craniocaudal views at subsequent screening examinations
started in The Netherlands. Also, during this period some
radiologists synchronous read mammograms made using FFDM
and SFM. Both effects could have influenced recall or detection
rate for both SFM and FFDM. However, in our data we did not
find an increased recall or detection rate for SFM after
subsequent screening examination, indicating that these effects
were negligible.
These data show that FFDM can be safely used for screening
purposes. The easier image transfer capabilities of FFDM may
prevent repeating the mammography during diagnostic work-up in
the hospital. Further research on possible effects of the higher recall
rate on the number of biopsies performed in patients with a false-
positive result might add to the comparison of FFDM and SFM, as
can future research of the proportion of T1a tumours, hormone
receptor and HER2 status.
In conclusion, FFDM resulted in similar rates of screen-
detected and interval cancers compared with SFM. This indicates
that FFDM performs as well as SFM in a breast cancer screening
program, with more ductal and high-grade invasive cancers
found after subsequent screens. No signs of an increase in low-
grade DCIS (which might connote possible overdiagnosis) were
seen. Nonetheless, after initial screening, which accounts for 12%
of all screens, FFDM resulted in higher recall rate and lower PPV
that requires attention.
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